Advances in therapeutics and imaging
GlyTherix Ltd is an Australian radiotherapy company specialising in therapeutics for solid tumors, expressing Glypican-1 (GPC-1).
Glytherix
GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, lung and ovarian cancers. It is not detectable in healthy tissue.
The company has a strong intellectual property position covering both its anti-GPC-1 antibody and the antigen itself, GPC-1.
This provides robust and long-term protection for the commercialisation of important new treatments to people with little hope.
GlyTherix has now completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse events observed.
GlyTherix is interested in partnerships or collaborations with larger pharmaceutical partners.